Literature DB >> 29399114

Mechanism for carbapenem resistance of clinical Enterobacteriaceae isolates.

Yafei Ye1, Lijuan Xu1, Yanping Han1, Zhe Chen1, Cailin Liu1, Liang Ming1.   

Abstract

Carbapenemase-producing 'super bacteria', particularly NDM-1 and its variants, have become a major public health concern worldwide. The present study aimed to explore the molecular mechanism for carbapenem resistance of clinical Enterobacteriaceae isolates. Seventy-eight non-repeated Enterobacteriaceae strains resistant to any carbapenem were screened at the First Affiliated Hospital of Zhengzhou University (Zhengzhou, China) between December 2011 and December 2015. Outer membrane porin (OMP) proteins were detected using SDS-PAGE. Carbapenemases, extended-spectrum β-lactamases (ESBLs) and plasmid AmpC enzyme genes were detected using polymerase chain reaction (PCR). PCR and SDS-PAGE demonstrated that 60.3% (47/78) of the strains produced carbapenemases, of which 33.3% (26/78) produced KPC-2 carbapenemase, suggesting that the strains resisted carbapenems primarily through carbapenemases. SDS-PAGE showed that the OMP proteins in the majority of carbapenem-resistant Enterobacteriaceae (CRE) strains were deleted or decreased compared with those in the sensitive strains. Of the 44 Klebsiella strains, 59.1% (26/44) did not express or expressed less OmpK35 or OmpK36. Among the 34 strains of other enterobacteria, 97.1% (33/34) did not express or expressed less OmpC or OmpF. Of all CRE strains, 35.9% (28/78) lost at least one OMP protein, indicating that the strains resisted carbapenems also by producing ESBLs and/or plasmid AmpC enzyme, as well as by losing OMP proteins. The resistance of clinically isolated CRE strains may primarily be attributed to the production of carbapenemases, and may also involve the deletion of OMP proteins or mutation of OMP genes.

Entities:  

Keywords:  SDS-PAGE; carbapenem-resistant enterobacteriaceae; polymerase chain reaction

Year:  2017        PMID: 29399114      PMCID: PMC5772903          DOI: 10.3892/etm.2017.5485

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  18 in total

Review 1.  Emerging issues in gram-negative bacterial resistance: an update for the practicing clinician.

Authors:  Shawn Vasoo; Jason N Barreto; Pritish K Tosh
Journal:  Mayo Clin Proc       Date:  2015-03       Impact factor: 7.616

2.  Favourable outcome in the treatment of carbapenem-resistant Enterobacteriaceae urinary tract infection with high-dose tigecycline.

Authors:  K Brust; A Evans; R Plemmons
Journal:  J Antimicrob Chemother       Date:  2014-05-30       Impact factor: 5.790

Review 3.  Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention.

Authors:  Neil Gupta; Brandi M Limbago; Jean B Patel; Alexander J Kallen
Journal:  Clin Infect Dis       Date:  2011-07-01       Impact factor: 9.079

4.  Outbreak due to a Klebsiella pneumoniae strain harbouring KPC-2 and VIM-1 in a German university hospital, July 2010 to January 2011.

Authors:  J Steinmann; M Kaase; S Gatermann; W Popp; E Steinmann; M Damman; A Paul; F Saner; J Buer; Pm Rath
Journal:  Euro Surveill       Date:  2011-08-18

5.  Multicenter Clinical and Molecular Epidemiological Analysis of Bacteremia Due to Carbapenem-Resistant Enterobacteriaceae (CRE) in the CRE Epicenter of the United States.

Authors:  Michael J Satlin; Liang Chen; Gopi Patel; Angela Gomez-Simmonds; Gregory Weston; Angela C Kim; Susan K Seo; Marnie E Rosenthal; Steven J Sperber; Stephen G Jenkins; Camille L Hamula; Anne-Catrin Uhlemann; Michael H Levi; Bettina C Fries; Yi-Wei Tang; Stefan Juretschko; Albert D Rojtman; Tao Hong; Barun Mathema; Michael R Jacobs; Thomas J Walsh; Robert A Bonomo; Barry N Kreiswirth
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

Review 6.  Carbapenem resistance in Enterobacteriaceae: here is the storm!

Authors:  Patrice Nordmann; Laurent Dortet; Laurent Poirel
Journal:  Trends Mol Med       Date:  2012-04-03       Impact factor: 11.951

7.  Activity of BAL30072 alone or combined with β-lactamase inhibitors or with meropenem against carbapenem-resistant Enterobacteriaceae and non-fermenters.

Authors:  Shazad Mushtaq; Neil Woodford; Russell Hope; Rachael Adkin; David M Livermore
Journal:  J Antimicrob Chemother       Date:  2013-02-28       Impact factor: 5.790

8.  Clinical and microbiological determinants of severe and fatal outcomes in patients infected with Enterobacteriaceae producing extended-spectrum β-lactamase.

Authors:  L Surgers; A Boyd; P-Y Boelle; V Lalande; P-A Jolivot; P-M Girard; G Arlet; C Cambier; A Homor; D Decre; J-L Meynard
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-02-08       Impact factor: 3.267

Review 9.  Combination therapy for carbapenem-resistant Gram-negative bacteria.

Authors:  Mical Paul; Yehuda Carmeli; Emanuele Durante-Mangoni; Johan W Mouton; Evelina Tacconelli; Ursula Theuretzbacher; Cristina Mussini; Leonard Leibovici
Journal:  J Antimicrob Chemother       Date:  2014-05-28       Impact factor: 5.790

10.  Complete sequencing of pNDM-HK encoding NDM-1 carbapenemase from a multidrug-resistant Escherichia coli strain isolated in Hong Kong.

Authors:  Pak Leung Ho; Wai U Lo; Man Kiu Yeung; Chi Ho Lin; Kin Hung Chow; Irene Ang; Amy Hin Yan Tong; Jessie Yun-Juan Bao; Si Lok; Janice Yee Chi Lo
Journal:  PLoS One       Date:  2011-03-21       Impact factor: 3.240

View more
  24 in total

1.  Cross-Resistance and the Mechanisms of Cephalosporin-Resistant Bacteria in Urinary Tract Infections Isolated in Indonesia.

Authors:  Aya Ishii; Katsumi Shigemura; Koichi Kitagawa; Mizuki Harada; Yuki Kan; Fuka Hayashi; Kayo Osawa; K Kuntaman; Toshiro Shirakawa; Masato Fujisawa
Journal:  Curr Microbiol       Date:  2021-03-13       Impact factor: 2.188

2.  Novel Carbapenem-Resistant Klebsiella pneumoniae ST147 Coharboring bla NDM-1, bla OXA-48 and Extended-Spectrum β-Lactamases from Pakistan.

Authors:  Aamir Jamal Gondal; Sidrah Saleem; Shah Jahan; Nakhshab Choudhry; Nighat Yasmin
Journal:  Infect Drug Resist       Date:  2020-07-02       Impact factor: 4.003

3.  First description of antimicrobial resistance in carbapenem-susceptible Klebsiella pneumoniae after imipenem treatment, driven by outer membrane remodeling.

Authors:  Xuebin Tian; Qiongdan Wang; Laura Perlaza-Jiménez; Xiangkuo Zheng; Yajie Zhao; Vijay Dhanasekaran; Renchi Fang; Jiahui Li; Chong Wang; Haiyang Liu; Trevor Lithgow; Jianming Cao; Tieli Zhou
Journal:  BMC Microbiol       Date:  2020-07-20       Impact factor: 3.605

4.  An Unusual Carbapenem Resistant Escherichia coli Carrying Plasmid-mediated AmpC and Mutated ompC in A Patient with Recurrent Urinary Tract Infections.

Authors:  Paige M K Larkin; Susan Realegeno; Kevin W Ward; Omai B Garner; Shangxin Yang
Journal:  IDCases       Date:  2020-05-04

5.  Characteristics of NDM-1-producing Klebsiella pneumoniae ST234 and ST1412 isolates spread in a neonatal unit.

Authors:  Xu Huang; Xiangjun Cheng; Pengfei Sun; Chenjie Tang; Fang Ni; Genyan Liu
Journal:  BMC Microbiol       Date:  2018-11-14       Impact factor: 3.605

6.  High frequency and molecular epidemiology of metallo-β-lactamase-producing gram-negative bacilli in a tertiary care hospital in Lahore, Pakistan.

Authors:  Noor Ul Ain; Anam Iftikhar; Syeda Sadia Bukhari; Samyyia Abrar; Shahida Hussain; Muhammad Hayat Haider; Farhan Rasheed; Saba Riaz
Journal:  Antimicrob Resist Infect Control       Date:  2018-11-03       Impact factor: 4.887

Review 7.  Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections.

Authors:  Sohita Dhillon
Journal:  Drugs       Date:  2018-08       Impact factor: 9.546

8.  Imipenem resistance in clinical Escherichia coli from Qom, Iran.

Authors:  Saeed Shams; Ali Hashemi; Mohammad Esmkhani; Somaye Kermani; Elham Shams; Alessandra Piccirillo
Journal:  BMC Res Notes       Date:  2018-05-18

9.  Phenotypic and genotypic characterization of clinical carbapenem-resistant Enterobacteriaceae isolates from Sokoto, northwest Nigeria.

Authors:  A Olowo-Okere; Y K E Ibrahim; B O Olayinka; J O Ehinmidu; Y Mohammed; L Z Nabti; J-M Rolain; S M Diene
Journal:  New Microbes New Infect       Date:  2020-08-01

10.  Ex Vivo Characterization of Effects of Renal Replacement Therapy Modalities and Settings on Pharmacokinetics of Meropenem and Vaborbactam.

Authors:  Fekade B Sime; Saurabh Pandey; Nermin Karamujic; Suzanne Parker; Elizabeth Alexander; Jeffery Loutit; Stephanie Durso; David Griffith; Jeffrey Lipman; Steven C Wallis; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.